ESOC Symposia on Medscape

Language translations (subtitles and transcripts) are available in French, German, Italian, Portuguese, Spanish and Chinese.

Symposia 1: "Preventing the Next Stroke: Factor XIa Inhibition From Evidence to Practice" 

Target Audience and Goal Statement

This educational activity is intended for an audience of neurologists, cardiologists, hematologists, primary care physicians, and nurses.

The goal of this activity is for learners to be better able to evaluate the role of factor XIa inhibitors within the broader landscape of secondary stroke prevention, from scientific evidence to clinical application.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Pharmacologic rationale for targeting factor XI/XIa to prevent thrombosis
  • Clinical evidence for factor XIa inhibitors in secondary stroke prevention
  • Clinical profiles of patients who may benefit from factor XIa inhibition
• Demonstrate greater confidence in their ability to

  • Recall the potential role of factor XIa inhibitors in future clinical practice

     

Chair

Ashkan Shoamanesh, MD

Associate Professor of Medicine
Division of Neurology
Stroke Neurologist
Marta and Owen Boris Chair in Stroke Research and Care 
McMaster University
Founding Director, Hemorrhagic Stroke Research Program
Hamilton, Ontario, Canada

Symposia 2: "Personalizing Antithrombotic Care: A Case-Based Look at Factor XIa Inhibition After Stroke" 

Target Audience and Goal Statement

This educational activity is intended for an audience of neurologists, cardiologists, hematologists, primary care physicians, and nurses.

The goal of this activity is for learners to be better able to evaluate the role of FXIa inhibitors in the secondary stroke prevention landscape by applying clinical evidence to patient case scenarios.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • The unmet needs in secondary stroke prevention with current antithrombotic therapies
  • The clinical evidence for FXIa inhibitors in secondary stroke prevention
• Demonstrate greater confidence in their ability to
  • Identify the most appropriate patients who may benefit from treatment with FXIa inhibitors

  • Discuss the potential role of FXIa inhibitors in secondary stroke prevention with peers

     

Chair

Mike Sharma, MD, MSc, FRCPC

Professor of Medicine, Neurology
Michael G. Degroote Chair in Stroke Prevention
McMaster University
Senior Scientist
Population Health Research Institute
Hamilton Health Sciences
Hamilton, Ontario, Canada

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

MA-M_ASUN-CA-0022-1